<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/EEA90A41-FE78-4648-A169-978B7D07858E"><gtr:id>EEA90A41-FE78-4648-A169-978B7D07858E</gtr:id><gtr:firstName>Assan</gtr:firstName><gtr:surname>Jaye</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U190085847"><gtr:id>9E564B39-76B2-4CAD-9724-4C7AFAEA7A6A</gtr:id><gtr:title>Characterisation of mycobacterial immunity during progression to AIDS and reversal on ART</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U190085847</gtr:grantReference><gtr:abstractText>Patients infected with HIV are more likely to suffer from tuberculosis (TB) disease caused by a germ called Mycobacterium than non infected individuals. The mechanisms underlying re-activation remain poorly understood regardless of HIV status and are crucial for rational design of vaccines.We want to study the quality of immune response to mycobacterial infection in HIV infected patients, examine the effect of the Antiretroviral Therapy (ART) on these responses and compare it from HIV infected healthy individuals and patients with HIV disease.</gtr:abstractText><gtr:technicalSummary>Infection with HIV leads to higher susceptibility to mycobacterial infections and progression to tuberculosis (TB) disease. Patients with advanced HIV are 100 times more likely to re-activate latent infection than immune competent individuals. The mechanisms underlying re-activation remain poorly understood regardless of HIV status and are crucial for rational design of vaccines.

We hypothesize that as CD4 T cell counts decline mechanisms that control mycobacterial infection deteriorate and that such mechanisms partly reappear during immune reconstitution. Furthermore, the number of subjects responding to TB antigens will decline and the quality of the response will change from a broad-spectrum cytokine product to interferon gamma (IFN-g) only response. Our long-term objectives are to study the quality of immune response to mycobacterial antigens in HIV patients with differing levels of immunosuppression caused either by declining or rising CD4 counts. Specifically, we will examine MTB-specific T cell responses during varying degrees of HIV-induced immunosuppression, and examine the effect of ART on these responses by detailed flowcytometric analysis. We will focus on MTB-specific CD8 T cells as they have been implicated in the long-term control of MTB infection. To that end we will phenotype antigen-specific na&amp;iuml;ve, effector and memory subsets from infected healthy and diseased HIV individuals.

The overall strategy is therefore not only to utilize certain biomarkers to monitor and characterize immune responses related to MTB infection in HIV patients with low CD4 counts, but to explore the changes that occur when such individuals start therapy, and further predict the occurrence of immune reconstituted inflammatory syndrome.</gtr:technicalSummary><gtr:fund><gtr:end>2009-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>381438</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>MRC Open-Days for Public visit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:id>238247BC-4841-433C-8731-86B9784F80E6</gtr:id><gtr:impact>MRC Unit, The Gambia organised an Open Day for schools and the public. A specal day was dedicated for paliamentarians as well. Poster presentations and explanations were well received

Press reports of the Open Day on daily tabloids help dessiminate scientific information to the public.</gtr:impact><gtr:outcomeId>AB2DD1211E4</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>9C6E7C51-5D60-46FB-9819-62323B89FD68</gtr:id><gtr:title>Mycobacterial T cell responses in HIV-infected patients with advanced immunosuppression.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f7dade8ac247a685e3a355d13ad829c"><gtr:id>9f7dade8ac247a685e3a355d13ad829c</gtr:id><gtr:otherNames>Hammond AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>A892AB573EA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C0E947F-5F90-4F4F-B04B-4D1BF38535D7</gtr:id><gtr:title>Polyfunctional CD4(+) and CD8(+) T cell responses to tuberculosis antigens in HIV-1-infected patients before and after anti-retroviral treatment.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c721e059d2551533a2a9aa5e0ffde77b"><gtr:id>c721e059d2551533a2a9aa5e0ffde77b</gtr:id><gtr:otherNames>Sutherland JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_15883_23_20435929</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>238F4CF0-BB0D-4294-918C-9DE92B8EF30A</gtr:id><gtr:title>Protection versus pathology in aviremic and high viral load HIV-2 infection-the pivotal role of immune activation and T-cell kinetics.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26eb95f4f944a87818ca7d604e361952"><gtr:id>26eb95f4f944a87818ca7d604e361952</gtr:id><gtr:otherNames>Hegedus A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>546257d3c42d24.34503661</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U190085847</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>